Intellia director awarded shares and options
Intellia Therapeutics director Frank Verwiel received new equity awards.
Rhea-AI Filing Summary
Intellia Therapeutics director Frank Verwiel received new equity awards. He was granted 9,200 restricted stock units, each representing a contingent right to receive one share of Intellia common stock. Following this grant, he holds 35,148 common shares directly.
He was also awarded a stock option for 13,300 shares of common stock at an exercise price of $12.89 per share. This option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders, and expires on June 8, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 13,300 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 9,200 | $0.00 | $0.00 |
Footnotes (2)
- F1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
- F2. This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Key Figures
Key Terms
restricted stock units financial
Stock Option (right to buy) financial
exercise price financial
vests in full financial
annual meeting of stockholders financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Intellia Therapeutics (NTLA) report for Frank Verwiel?
What are the details of the stock option granted to Frank Verwiel at Intellia (NTLA)?
What does the 9,200 restricted stock unit grant at Intellia (NTLA) represent?
When does Frank Verwiel’s new Intellia (NTLA) stock option expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.